少妇人妻无码专区毛片_蝌蚪视频窝在线播放_欧美性色欧美A在线播放_尤物在线精品视频_欧美精品国产一区二区三区_在线观看成人无码中文AV天堂不卡

美國AmProtein   
AmProtein由Amgen前蛋白質(zhì)生產(chǎn)科學家Matthew Hui博士創(chuàng)建于2002年。
AmProtein發(fā)現(xiàn)了以DNA物理結(jié)構(gòu)為基礎(chǔ)的所有真核細胞通用的基因表達機制，無鼓泡的新型傳氧機制，為現(xiàn)代生物技術(shù)做出了巨大貢獻。

AmProtein將以DNA物理結(jié)構(gòu)為基礎(chǔ)的真核細胞通用基因表達機制此種機制定義為“GC-rich方法”。它將引領(lǐng)基因擴增后第二次生物革命，并帶領(lǐng)世界商業(yè)化生物研究進入一個全新的領(lǐng)域。基于這種GC-rich方法，AmProtein發(fā)展出一套應(yīng)用于哺乳動物細胞，雞細胞，魚細胞和可能的植物細胞基因表達載體并將其商業(yè)化，僅僅通過一些實驗室規(guī)模的穩(wěn)定的基因轉(zhuǎn)染便可得到商業(yè)需求水平的蛋白質(zhì)濃度。

基于無鼓泡式新型傳氧機制，AmProtein成功開發(fā)出一次性生物工藝用塑料袋并已作商業(yè)化生產(chǎn)，可為高密度細胞提供高效溶氧的培養(yǎng)條件。在此基礎(chǔ)上，AmProtein成功的衍生出了一套高密度細胞灌注培養(yǎng)系統(tǒng)。我們采用一次性的細胞貼壁紙片材料，并且使用懸浮培養(yǎng)系統(tǒng)作為溶氧生成器。

AmProtein將其高效表達系統(tǒng)應(yīng)用于雙體藥物開發(fā)和快速生產(chǎn)，這將是生物技術(shù)的一次突破。AmProtein的載體系列和蛋白生產(chǎn)平臺是快速發(fā)展重組蛋白、抗體、基因藥物的理想選擇。

AmProtein的表達載體和反應(yīng)器系列均擁有世界專利，可根據(jù)客戶需求提供相應(yīng)許可。AmProtein擁有雄厚的科研力量，我們接受合同服務(wù)承接各大公司的項目及課題。

AmProtein將對全世界開放，尋求高瞻遠矚的合作者共同開發(fā)技術(shù)。目前我們在中國和美國的合作者都已開始分享AmProtein的技術(shù)帶來的豐碩果實，我們在中國的合作者包括哈藥集團，華北制藥，西安新藥中心，杭州安瑞普生物科技有限公司www.amprotein-china.com。在美國，AmProtein是加利福尼亞生物技術(shù)研究協(xié)會的成員，該技術(shù)研究協(xié)會由著名的前Amgen公司的科學家組成，更多信息請登陸：www.calbioresearch.com
AmProtein和華北制藥集團新藥研究中心、哈爾濱制藥集團技術(shù)中心、哈藥生物以及西安新藥評價研究中心形成緊密的技術(shù)和生產(chǎn)聯(lián)盟,以杭州為中心,已形成一個國際生物高技術(shù)平臺,為中國奠定了生物工業(yè)基礎(chǔ)。

AmProtein由六大功能區(qū)組成，其中五個研究方向是基于AmProtein在基因表達和傳氧機制的重大世界性突破。我們的專利和概念已經(jīng)擴展為橫跨多個生物技術(shù)工程領(lǐng)域的一整條產(chǎn)業(yè)鏈。

AmProtein家族：

● 生物反應(yīng)器&培養(yǎng)基

1、激流式懸浮&灌注生物反應(yīng)器系統(tǒng)

2、模擬反應(yīng)器系統(tǒng)

3、配套附件

● 表達系統(tǒng)

1、用于哺乳動物，魚&雞的pMH3-5 載體系列

2、來源于植物的載體系列正在研發(fā)中

● 醫(yī)療設(shè)備

“人工肺”心臟旁路溶氧生成器用于安全的長時間全血細胞培養(yǎng)&傳氧

● 疫苗

1、關(guān)于哺乳動物，魚和雞疫苗生產(chǎn)高密度細胞培養(yǎng)工藝的突破

2、關(guān)于人類疫苗生產(chǎn)高密度細胞培養(yǎng)工藝的突破

● 治療&合同服務(wù)

1、雙體藥物

2 、Hyper-G融合技術(shù)（取代Pegylation方法）

3、改制藥與改制藥仿制

● 市場

全球商業(yè)數(shù)據(jù)庫

 
AmProtein is a biotech company founded in 2002 by Matthew Hui, MD, PhD, formerly a key protein production scientist at Amgen. AmProtein has developed a reputation as a biotechnology powerhouse that has revolutionized the modern biotechnology industry with the discovery of a DNA physical structure-based gene expression mechanism, common to all eukaryotic cells, and a novel, non-sparging-dependent O2 transfer method.

AmProtein has termed this mechanism the 'GC-rich method.' It has led to a second revolution after the gene amplification method, and has surely resulted in a new era in commercialized biologics research worldwide. Based on the GC-rich method, AmProtein has developed and commercialized a gene expression vector series for mammalian cells, chicken cells, fish cells, and possibly plant cells. By using the GC-rich method, one can reach commercial level protein titers after only a few laboratory-scale stable gene transfections.

Based on the above non-sparging O2 transfer method, we have successfully commercialized a single-use, plastic bag-based bioreactor series as an effective dissolved oxygen (DO) generator for high-density suspension cell culture.

In addition, AmProtein has successfully developed a high-density perfusion cell culture system by using a single-use, cell attachment paper-carrier material and our suspension culture system as a DO generator.

AmProtein has applied its expression system for the rapid production and subsequent development of our dual domain drug product candidates, the next IP frontier in biologics. AmProtein's vector series and protein production platform are ideal for the rapid development of recombinant protein, antibody, and generic drugs. Both AmProtein's revolutionary expression vector and superior bioreactor series are available for licensing. Also, AmProtein has the capability to support the projects of other companies through its Contract Research division.

AmProtein is open to fostering partnerships around the globe for the co-development of its technologies. Currently we enjoy fruitful collaborations is China and the United States. Our partners in China include Harbin Pharmaceutical Group Corporation, North China Pharmaceutical Corporation, Xian Drug Evaluation Center, and Hangzhou AmProtein Biotechnology Co., Ltd. www.amprotein-china.com. In America, AmProtein is a part of the California Biotechnology Research Consortium. The Consortium consists of companies started by well-known ex-Amgen scientists. See www.calbioresearch.com for more information.